Article
An engineered IL-21 variant is a potent antitumor candidate for antitumor immunotherapy.
Acta pharmacologica Sinica - 1 Mar 2026
Wu Hui, Cheng Ya-Ping, Liu Yu-Long, Zhu Ruo-Han, Ji Li-Wen, Wang Ming-Kai, Li Quan-Xiao, Shen Zhao-Ling, Ying Tian-Lei, Wu Yan-Ling
Abstract excerpt
IL-21, as an immune agonist, has demonstrated limited therapeutic efficacy in cancer immunotherapy. To overcome this inherent limitation, we constructed a yeast surface-displayed IL-21 mutant library guided by the structure of the IL-21/IL-21 receptor (IL-21R). Following one round of magnetic bead sorting and three rounds of fluorescence-activated cell sorting, several variants were isolated and evaluated for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
